Canada has approved a drug that can slow the progression of Alzheimer’s disease

October 27,2025

RED FM News Desk

Health Canada has approved lecanemab (brand name Leqembi), an expensive new drug that slows the progression of Alzheimer’s disease by targeting its root cause rather than just treating symptoms. It’s the first medication in Canada proven to reduce cognitive and functional decline by clearing beta-amyloid protein buildup in the brain. 

The drug, developed by Eisai Ltd. and Biogen Inc., received conditional approval after a review lasting over two years. It has already been approved in more than 50 countries, including the U.S., Japan, and those in the EU. In the U.S., it costs about US$26,500 per year and requires regular MRIs to monitor for rare side effects such as brain swelling or microbleeds. 

Experts describe lecanemab as a major step forward, offering early-stage Alzheimer’s patients up to 10–13 months of delayed disease progression, allowing them to stay independent longer. However, neurologists caution it is not a cure, benefits only those in early stages, and may face accessibility challenges in Canada due to high costs, limited specialist availability, and MRI shortages. 

Dr. Sharon Cohen, who led Canadian clinical trials, says patients could start receiving treatment by late 2025. She and other experts hope it will eventually be covered by public health plans, emphasizing that delaying severe symptoms could significantly reduce long-term healthcare and caregiving costs. 

This marks the first Alzheimer’s drug approval in Canada in over 25 years, representing what researchers call a “major advancement” in dementia treatment.